Use of bisphosphonates for the treatment of stress fractures in athletes

Knee Surgery, Sports Traumatology, Arthroscopy

Volumn 17, Issue 5, 2009, Pages 542-550

  Shima, Yosuke ^a,c   Engebretsen, Lars ^b   Iwasa, Junji ^a   Kitaoka, Katsuhiko ^d   Tomita, Katsuro ^d  

^a NORWEGIAN SCHOOL OF SPORT SCIENCES   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bisphosphonates; Bone remodeling; Microdamage; Stress fracture; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ANIMAL; ARTICLE; BONE REMODELING; DRUG EFFECT; FRACTURE HEALING; HUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SPORT INJURY; STRESS FRACTURE; TREATMENT OUTCOME;

ANIMALS; ATHLETIC INJURIES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; FRACTURE HEALING; FRACTURES, STRESS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 67349172129     PISSN: 09422056     EISSN: 14337347     Source Type: Journal    
DOI: 10.1007/s00167-008-0673-0     Document Type: Article

References (84)

1. S Adami AK Bhalla R Dorizzi F Montesanti S Rosini G Salvagno V Lo Cascio 1987 The acute-phase response after bisphosphonate administration Calcif Tissue Int 41 326 331
2. SM Ali FJ Esteva G Hortobagyi H Harvey J Seaman R Knight L Costa A Lipton 2001 Safety and efficacy of bisphosphonates beyond 24 months in cancer patients J Clin Oncol 19 3434 3437
3. MR Allen K Iwata R Phipps DB Burr 2006 Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate Bone 39 872 879
4. N Amanat R Brown LE Bilston DG Little 2005 A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair J Orthop Res 23 1029 1034
5. N Amanat M [tmp] McDonald C Godfrey L Bilston D Little 2007 Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair J Bone Miner Res 22 867 876
6. JG Barrett SJ Sample J [tmp] McCarthy VL Kalscheur P Muir L Prokuski 2007 Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats J Orthop Res 25 1070 1077
7. F Bauss RK Schenk S Hört B Müller-Beckmann G Sponer 2004 New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate J Pharmacol Toxicol Methods 50 25 34
8. KL Bennell SA Malcolm PD Brukner RM Green JL Hopper JD Wark PR Ebeling 1998 A 12-month prospective study of the relationship between stress fractures and bone turnover in athletes Calcif Tissue Int 63 80 85
9. JR Berenson L Rosen R Vescio HS Lau M Woo A Sioufi MO Kowalski RD Knight JJ Seaman 1997 Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function J Clin Pharmacol 37 285 290
10. JP Bilezikian 2006 Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med 355 2278 2281
11. DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings FLEX Research Group 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial JAMA 296 2927 2938
12. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings HORIZON Pivotal Fracture Trial 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822
13. JJ Body I Mancini 2002 Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10 399 407
14. JJ Body 2005 Bisphosphonates in metastatic bone disease: renal safety matters Oncologist 10 1 2
15. HG Bone D Hosking JP Devogelaer JR Tucci RD Emkey RP Tonino JA Rodriguez-Portales RW Downs J Gupta AC Santora UA Liberman Alendronate Phase III Osteoporosis Treatment Study Group 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199
16. R Bransford E Goergens J Briody N Amanat A Cree D Little 2007 Effect of zoledronic acid in an L6-L7 rabbit spine fusion model Eur Spine J 16 557 562
17. DB Burr C Milgrom RD Boyd WL Higgins G Robin EL Radin 1990 Experimental stress fractures of the tibia. Biological and mechanical aetiology in rabbits J Bone Joint Surg Br 72 370 375
18. DB Burr MR Forwood DP Fyhrie RB Martin MB Schaffler CH Turner 1997 Bone microdamage and skeletal fragility in osteoporotic and stress fractures J Bone Miner Res 12 6 15
19. Burr DB (2001) Pharmaceutical treatments that may prevent or delay the onset of stress fractures. In: Burr DB, Milgrom C (eds) Muscloskeletal fatigue and stress fractures. CRC Press, Boca Raton, pp 259-270
20. Y Cao S Mori T Mashiba MS Westmore L Ma M Sato T Akiyama L Shi S Komatsubara K Miyamoto H Norimatsu 2002 Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats J Bone Miner Res 17 2237 2246
21. JA Eisman R Civitelli S Adami E Czerwinski C Recknor R Prince JY Reginster M Zaidi D Felsenberg C Hughes N Mairon D Masanauskaite DM Reid PD Delmas RR Recker 2008 Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA Study J Rheumatol 35 488 497
22. A Ezra G Golomb 2000 Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption Adv Drug Deliv Rev 42 175 195
23. R Felix JD Bettex H Fleisch 1981 Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells Calcif Tissue Int 33 549 552
24. SD Flinn 2002 Changes in stress fracture distribution and current treatment Curr Sports Med Rep 1 272 277
25. L Flora GS Hassing GG Cloyd JA Bevan AM Parfitt AR Villanueva 1981 The long-term skeletal effects of EHDP in dogs Metab Bone Dis Relat Res 3 289 300
26. P Fournier S Boissier S Filleur J Guglielmi F Cabon M Colombel P Clézardin 2002 Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 6538 6544
27. RM Gehrmann RL Renard 2006 Current concepts review: Stress fractures of the foot Foot Ankle Int 27 750 757
28. SL Hame JM LaFemina DR [tmp] McAllister GW Schaadt FJ Dorey 2004 Fractures in the collegiate athlete Am J Sports Med 32 446 451
29. MR Hausman MB Schaffler RJ Majeska 2001 Prevention of fracture healing in rats by an inhibitor of angiogenesis Bone 29 560 564
30. G Jackson 2005 Safety and compliance of intravenous and oral dosing regimens Oncologist 10 313 314
31. CC Kaeding 2006 Stress fractures Clin Sports Med 25 15 16
32. MC Koester KP Spindler 2006 Pharmacologic agents in fracture healing Clin Sports Med 25 63 73
33. R Korpelainen S Orava J Karpakka P Siira A Hulkko 2001 Risk factors for recurrent stress fractures in athletes Am J Sports Med 29 304 310
34. AH Kurth C Eberhardt S Müller M Steinacker M Schwarz F Bauss 2005 The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats Bone 37 204 210
35. KA Lai WJ Shen CY Yang CJ Shao JT Hsu RM Lin 2005 The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study J Bone Joint Surg Am 87 2155 2159
36. BA Lenart DG Lorich JM Lane 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate N Engl J Med 358 1304 1306
37. C Li S Mori J Li Y Kaji T Akiyama J Kawanishi H Norimatsu 2001 Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats J Bone Miner Res 16 429 436
38. JH Lin 1996 Bisphosphonates: a review of their pharmacokinetic properties Bone 18 75 85
39. DG Little MS Cornell MS Hile J Briody CT Cowell L Bilston 2001 Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis Injury 32 SD14 SD20
40. DG Little NC Smith PR Williams JN Briody LE Bilston EJ Smith EM Gardiner CT Cowell 2003 Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis J Bone Miner Res 18 1300 1307
41. DG Little RA Peat A Mcevoy PR Williams EJ Smith PA Baldock 2003 Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats J Bone Miner Res 18 2016 2022
42. DG Little M [tmp] McDonald R Bransford CB Godfrey N Amanat 2005 Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model J Bone Miner Res 20 2044 2052
43. V Macarol FT Fraunfelder 1994 Pamidronate disodium and possible ocular adverse drug reactions Am J Ophthalmol 118 220 224
44. B Martin 1995 Mathematical model for repair of fatigue damage and stress fracture in osteonal bone J Orthop Res 13 309 316
45. RE Marx 2003 Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 61 1115 1117
46. T Mashiba T Hirano CH Turner MR Forwood CC Johnston DB Burr 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib J Bone Miner Res 15 613 620
47. T Mashiba CH Turner T Hirano MR Forwood CC Johnston DB Burr 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone 28 524 531
48. C Milgrom A Simkin A Eldad M Nyska A Finestone 2000 Using bone's adaptation ability to lower the incidence of stress fractures Am J Sports Med 28 245 251
49. C Milgrom A Finestone N Sharkey A Hamel V Mandes D Burr A Arndt I Ekenman 2002 Metatarsal strains are sufficient to cause fatigue fracture during cyclic overloading Foot Ankle Int 23 230 235
50. C Milgrom A Finestone V Novack D Pereg Y Goldich Y Kreiss E Zimlichman S Kaufman M Liebergall D Burr 2004 The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits Bone 35 418 424
51. O Miltner C Niedhart W Piroth M Weber CH Siebert 2003 Transient osteoporosis of the navicular bone in a runner Arch Orthop Trauma Surg 123 505 508
52. DH Minsker JM Manson CP Peter 1993 Effects of the bisphosphonate, alendronate, on parturition in the rat Toxicol Appl Pharmacol 121 217 223
53. MJ Murguia A Vailas B Mandelbaum J Norton J Hodgdon H Goforth M Riedy 1988 Elevated plasma hydroxyproline. A possible risk factor associated with connective tissue injuries during overuse Am J Sports Med 16 660 664
54. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301
55. SM Ott 2001 Fractures after long-term alendronate therapy J Clin Endocrinol Metab 86 1835 1836
56. L Parker 1999 I.v. devices and related infections: causes and complications Br J Nurs 8 1491 1498
57. N Patlas G Golomb P Yaffe T Pinto E Breuer A Ornoy 1999 Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats Teratology 60 68 73
58. M Pazianas P Miller WA Blumentals M Bernal P Kothawala 2007 A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics Clin Ther 29 1548 1558
59. M Pepper V Akuthota EC [tmp] McCarty 2006 The pathophysiology of stress fractures Clin Sports Med 25 1 16
60. M Ramachandran K Ward RR Brown CF Munns CT Cowell DG Little 2007 Intravenous BP therapy for traumatic osteonecrosis of the femoral head in adolescents J Bone Joint Surg Am 89 1727 1734
61. JD Ringe A Dorst H Faber 2005 Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate Osteoporos Int 16 2063 2068
62. JD Ringe JJ Body 2007 A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover Clin Exp Rheumatol 25 766 774
63. RG Russell NB Watts FH Ebetino MJ Rogers 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733 759
64. M Saito S Mori T Mashiba S Komatsubara K Marumo 2008 Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs Osteoporos Int 19 1343 1354
65. D Santini B Vincenzi S Galluzzo F Battistoni L Rocci O Venditti G Schiavon S Angeletti F Uzzalli M Caraglia G Dicuonzo G Tonini 2007 Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients Clin Cancer Res 13 4482 4486
66. SW Shaffer TL Uhl 2006 Preventing and treating lower extremity stress reactions and fractures in adults J Athl Train 41 466 469
67. E Shane S Goldring S Christakos M Drezner J Eisman S Silverman D Pendrys 2006 Osteonecrosis of the jaw: more research needed J Bone Miner Res 21 1503 1505
68. T Siegmund MR Allen DB Burr 2008 Failure of mineralized collagen fibrils: modeling the role of collagen cross-linking J Biomech 41 1427 1435
69. ES Siris 1993 Bisphosphonates and iritis Lancet 341 436 437
70. EJ Smith DG Little JN Briody A [tmp] McEvoy NC Smith JA Eisman EM Gardiner 2005 Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits J Bone Miner Res 20 1731 1741
71. GW Stewart ME Brunet MR Manning FA Davis 2005 Treatment of stress fractures in athletes with intravenous pamidronate Clin J Sport Med 15 92 94
72. M Taki O Iwata M Shiono M Kimura K Takagishi 2007 Extracorporeal shock wave therapy for resistant stress fracture in athletes: a report of 5 cases Am J Sports Med 35 1188 1192
73. D Thiébaud A Sauty P Burckhardt P Leuenberger L Sitzler JR Green A Kandra J Zieschang P Ibarra de Palacios 1997 An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates Calcif Tissue Int 61 386 392
74. K Thompson MJ Rogers 2004 Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro J Bone Miner Res 19 278 288
75. RP Tonino PJ Meunier R Emkey JA Rodriguez-Portales CJ Menkes RD Wasnich HG Bone AC Santora M Wu R Desai PD Ross 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group J Clin Endocrinol Metab 85 3109 3115
76. RP Tonino 2001 Safety of long-term alendronate J Clin Endocrinol Metab 86 1835 1836
77. EL van Meerten HM Kroon SE Papapoulos 1992 Epi- and metaphyseal changes in children caused by administration of bisphophonates Radiology 184 249 254
78. K Ward CT Cowell DG Little 2005 Quantification of metaphyseal modeling in children treated with bisphosphonates Bone 36 999 1002
79. VV Välimäki H Alfthan E Lehmuskallio E Löyttyniemi T Sahi H Suominen MJ Välimäki 2005 Risk factors for clinical stress fractures in male military recruits: a prospective cohort study Bone 37 267 273
80. RS Weinstein JR Chen CC Powers SA Stewart RD Landes T Bellido RL Jilka AM Parfitt SC Manolagas 2002 Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids J Clin Invest 109 1041 1048
81. MP Whyte D Wenkert KL Clements WH [tmp] McAlister S Mumm 2003 Bisphosphonate-induced osteopetrosis N Engl J Med 349 457 463
82. SB Woo JW Hellstein JR Kalmar 2006 Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 753 761
83. J Wood K Bonjean S Ruetz A Bellahcène L Devy JM Foidart V Castronovo JR Green 2002 Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J Pharmacol Exp Ther 302 1055 1061
84. DK Wysowski J Chang 2005 Alendronate and risedronate: reports of severe bone, joint, and muscle pain Arch Intern Med 165 346 347